Cas:116714-47-7 3-chloro-4-[1,1,2-trifluoro-2-(trifluoromethoxy)ethoxy]aniline manufacturer & supplier

Chemical Name:3-chloro-4-[1,1,2-trifluoro-2-(trifluoromethoxy)ethoxy]aniline

CAS.NO:116714-47-7

Synonyms:Novaluron Intermediate

Molecular Formula:C₉H₆ClF₆NO₂

Molecular Weight:309.59300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:294ºC

Density:1.546

Index of Refraction:1.451

PSA:44.48000

Exact Mass:308.99900

LogP:4.30700

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Novaluron Intermediate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Novaluron Intermediate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Novaluron Intermediate Use and application,Novaluron Intermediate technical grade,usp/ep/jp grade.

Related News: Pharmaceutical intermediates: chemical raw materials or chemical products used in the process of pharmaceutical synthesis, are intermediate products in the process of producing APIs, and can be further processed into APIs. 3-chloro-4-[1,1,2-trifluoro-2-(trifluoromethoxy)ethoxy]aniline manufacturer Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly. 3-chloro-4-[1,1,2-trifluoro-2-(trifluoromethoxy)ethoxy]aniline supplier Using a proprietary chemistry platform, Onconova has created a pipeline of targeted agents designed to work against specific cellular pathways that are important in cancer cells. 3-chloro-4-[1,1,2-trifluoro-2-(trifluoromethoxy)ethoxy]aniline vendor The drug substance is an active product that has completed the synthetic route, and the intermediate is a product in one place in the synthetic route. 3-chloro-4-[1,1,2-trifluoro-2-(trifluoromethoxy)ethoxy]aniline factory Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly.